The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Juluca - A Two-Drug Complete Regimen for HIV (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Juluca - A Two-Drug Complete Regimen for HIV (online only)
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), as a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Juluca - A Two-Drug Complete Regimen for HIV (online only)
Article code: 1561g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.